Lawrence Eichenfield, M.D.

Bio

Dr. Eichenfield is chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego and professor of dermatology and pediatrics and vice-chair of the department of dermatology at UC San Diego School of Medicine. He is board certified in dermatology, pediatric dermatology and pediatrics.

After earning his medical degree from Mount Sinai School of Medicine in New York, Dr. Eichenfield was a pediatric resident and chief resident at Children's Hospital of Philadelphia. He then completed his dermatology residency at the Hospital of the University of Pennsylvania.

Along with longstanding expertise in atopic dermatitis, acne, psoriasis and other inflammatory skin conditions, Dr. Eichenfield has interests in neonatal dermatology, vascular lesions, laser surgery and rare skin disorders. He has authored more than 400 journal articles, chapters, abstracts and books, and has served as the senior editor of "Neonatal and Infant Dermatology," published by Elsevier, as well as "The Eczemas." He served as editor-in-chief of Pediatric Dermatology for 12 years and currently serves on the editorial boards of multiple journals and periodicals.

Dr. Eichenfield has held multiple leadership positions, including co-founder and co-chair of the Pediatric Dermatology Research Alliance, co-chair of the American Academy of Dermatology Guidelines for Atopic Dermatitis, co-chair of the American Acne and Rosacea Society/American Academy of Pediatrics Pediatric Acne Recommendations for Diagnosis and Treatment, member of the Expert Panel Member of the NIAID Guidelines for Diagnosis and Management of Food Allergy, Scientific Advisory Board of the National Eczema Association, and director of the Rady Children's/UC San Diego Eczema and Inflammatory Skin Disease Center. Additionally, he has served in leadership roles on guidelines and consensus statements for multiple dermatological conditions, including acne, rosacea, atopic dermatitis and psoriasis.

Dr. Eichenfield enjoys running, reading, and skiing.

Publications

Is colloidal oat an effective emollient ingredient for the prevention and treatment of atopic dermatitis in infants?
Fowler JF, Ma L, Bergman J, Horowitz P, Lavender T, Eichenfield LF, Draelos Z, Danby SG, Cork MJ

Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic Dermatitis.
Simpson EL, Silverberg JI, Bissonnette R, Stein Gold L, Armstrong A, Hebert AA, Serrao RT, Jakus JR, Brown PM, Rubenstein DS, Piscitelli SC, Tallman AM, Eichenfield LF

Orismilast, a phosphodiesterase 4B/D inhibitor, in moderate-to-severe atopic dermatitis: efficacy and safety from a multicentre randomized placebo-controlled phase IIb dose-ranging study (ADESOS).
Silverberg JI, Eichenfield LF, Blauvelt A, Irvine AD, Guttman-Yassky E, Langley RG, Warren RB, French LE, Felding J, Weiss A, Pedersen CB, Jensen ML, Carlsson A, Sommer MOA, Kjøller K, Simpson EL

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis.
Bissonnette R, Gold LS, Kircik L, Simpson EL, Eichenfield LF, Browning J, Hebert AA, Alexis AF, Soong W, Piscitelli SC, Tallman AM, Rubenstein DS, Brown PM, Silverberg JI

Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3, a Phase 3, Randomized Double-Blind Study.
Eichenfield LF, Stein Gold LF, Simpson EL, Zaenglein AL, Armstrong AW, Tollefson MM, Soong W, Lee LW, Devani AR, Forman SB, Siri DD, Kallender H, Angel B, Li Q, Chen X, Paller AS

Patient-Reported Impact of Atopic Dermatitis on Pediatric and Adolescent Patients With Moderate-To-Severe Disease: Results of a Real-World, Cross-Sectional Survey.
Eichenfield LF, Shi VY, Yu J, Pierce EJ, Atwater AR, Austin J, Anderson P, Paller AS

Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD Registry.
Eichenfield DZ, Knapp KD, Claxton A, Munoz B, Crawford JM, Balu S, Kim Y, Schneider S, Haft MA, Silverberg JI, Thaci D, Eichenfield LF, Bagel J, Rhoads JW, Paller AS, TARGET-DERM AD Investigators

Functional genotype classification groups distinguish disease severity in recessive dystrophic epidermolysis bullosa.
Pathmarajah P, Eid E, Nazaroff J, So J, Mittal V, Harris N, Li S, Lucky AW, Gorell ES, Peoples KG, Pope E, Lara-Corrales I, Paller AS, Wiss K, Perman MJ, Eichenfield LF, Levy ML, Morel KD, García-Romero MT, McCuaig CC, Saber M, Marinkovich MP, Oro A, Bruckner AL, Tang JY

Integrated Efficacy and Safety Analysis of Abrocitinib in Adolescents With Moderate-to-Severe Atopic Dermatitis.
Paller AS, Eichenfield LF, Irvine AD, Flohr C, Wollenberg A, Barbarot S, Bangert C, Spergel JM, Selfridge A, Biswas P, Fan H, Alderfer J, Watkins M, Koppensteiner H

Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial.
Eichenfield LF, Serrao R, Prajapati VH, Browning JC, Swanson L, Funk T, Gonzalez ME, Hebert AA, Lee M, Boguniewicz M, Simpson EL, Seal MS, Krupa D, Hanna D, Snyder S, Burnett P, Chu DH, Almaraz E, Higham RC, Berk DR

Low Infection Rates With Long-Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open-Label Extension Study.
Paller AS, Ramien M, Cork MJ, Simpson EL, Wine Lee L, Eichenfield LF, Khokhar FA, Coleman A, Gherardi G, Chen Z, Zhang A, Cyr SL

ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis.
Guttman-Yassky E, Simpson E, Bissonnette R, Eichenfield LF, Kabashima K, Luna PC, Hercogová JT, Spelman L, Worm M, Esfandiari E, Arai T, Mano H, Charuworn P, Wang A, Kricorian G

Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial.
Simpson EL, Eichenfield LF, Papp KA, Forman SB, Hebert AA, Gonzalez ME, Gooderham MJ, Hong HC, Prajapati VH, Guttman-Yassky E, Silverberg JI, Seal MS, Krupa D, Almaraz E, Hanna D, Burnett P, Snyder S, Chu DH, Higham RC, Berk DR

A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council.
Haag C, Alexis A, Aoki V, Bissonnette R, Blauvelt A, Chovatiya R, Cork MJ, Danby SG, Eichenfield LF, Eyerich K, Gooderham M, Guttman-Yassky E, Hijnen DJ, Irvine AD, Katoh N, Murrell DF, Leshem YA, Levin AA, Vittrup I, Olydam JI, Orfali RL, Paller AS, Renert-Yuval Y, Rosmarin D, Silverberg JI, Thyssen JP, Ständer S, Stefanovic N, Todd G, Yu J, Simpson EL

Managing Childhood and Adolescent Atopic Dermatitis in Primary Care: A US Expert Group Consensus.
Boguniewicz M, Levy ML, Eichenfield LF, Lauren CT, Leung DYM, Schneider LC, Siegfried EC, Tom WL, Paller AS

Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne in Children and Adolescents.
Eichenfield LF, Hebert AA, Harper JC, Baldwin H, Bhatia N, Gold LS, Kircik LH, Graber E, Tanghetti EA, Alexis AF, Del Rosso JQ

Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD Registry.
Haft MA, Knapp KD, Claxton A, Munoz B, Crawford JM, Balu S, Kim Y, Schneider S, Eichenfield DZ, Silverberg JI, Eichenfield LF, Bagel J, Rhoads JLW, Paller AS

Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years.
Wollenberg A, Ikeda M, Chu CY, Eichenfield LF, Seyger MMB, Prakash A, Angle R, Zhu D, Pontes M, Paller AS

Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks.
Paller AS, Mendes-Bastos P, Siegfried E, Eichenfield LF, Soong W, Prajapati VH, Lio P, Simpson EL, Raymundo EM, Suravaram S, Hu X, Yang Y, Huang X, Calimlim BM, Platt AM, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD

Approach to Mycosis Fungoides in children: Consensus-based recommendations.
Zvulunov A, Neale H, Stern J, Santaguida P, Stein AB, Koh M, Eichenfield LF, Guitart J, Goebeler M, Scarisbrick J, Willemze R, Coughlin CC, George R, Brazzelli V, Marschalkó M, Belousova I, Querfeld C, Bagot M, Szepietowski JC, Papadavid E, Quaglino P, Hoeger P, Ortiz-Romero PL, Nikolaou V, Dummer R, Aung PP, Lawley L, Morel KD, Ngan B, Wain M, Gameiro A, Lacy-Niebla RM, Pope E

Targeting the aryl hydrocarbon receptor as a strategy to expand the therapeutic armamentarium in atopic dermatitis.
Eichenfield LF, Silverberg JI, Hebert AA, Boguniewicz M

Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Participants With Moderate-to-Severe Acne: The Patient Journey.
Baldwin H, Harper JC, Zeichner JA, Draelos ZD, Eichenfield LF, Gold M, Gold LS, Kircik LH

Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History.
Blauvelt A, Kallender H, Sturm D, Li Q, Ren H, Eichenfield LF

Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials.
Simpson EL, Eichenfield LF, Alonso-Llamazares J, Draelos ZD, Ferris LK, Forman SB, Gooderham M, Gonzalez ME, Hebert AA, Kircik LH, Lomaga M, Moore A, Papp KA, Prajapati VH, Hanna D, Snyder S, Krupa D, Burnett P, Almaraz E, Higham RC, Chu DH, Berk DR

A Consensus on Staphylococcus aureus Exacerbated Atopic Dermatitis and the Need for a Novel Treatment.
Schachner LA, Andriessen A, Gonzalez ME, Lal K, Hebert AA, Eichenfield LF, Lio P

See the full listing of this physician's publications on PubMed, a service of the National Library of Medicine.

PubMed is a third-party website and not affiliated with Rady Children's Hospital-San Diego.